Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341 | 0.95 | CYP19A1 (0.36) | CYP19A1NQO2KDM4ELMNASOST | |
| SCHEMBL29565868 | 0.95 | CYP19A1 (0.36) | CYP19A1NQO2KDM4ELMNASOST | |
| SCHEMBL29424759 | 0.95 | CYP19A1 (0.36) | CYP19A1NQO2KDM4ELMNASOST | |
| SCHEMBL30393960 | 0.94 | CYP19A1 (0.35) | CYP19A1NQO2KDM4ELMNASOST | |
| Acetic Acid SCHEMBL29538014 | 0.88 | TARBP2 (0.34) | CYP19A1NQO2KDM4ELMNANQO1 | |
| SCHEMBL18810594 | 0.87 | POLB (0.33) | CYP19A1NQO2KDM4ELMNAACHE | |
| SCHEMBL431846 | 0.86 | KDM4E (0.32) | CYP19A1NQO2KDM4ELMNASOST | |
| SCHEMBL18187041 | 0.86 | — | — | |
| SCHEMBL1144617 | 0.84 | CYP19A1 (0.33) | CYP19A1NQO2 | |
| SCHEMBL5896988 | 0.82 | NQO2 (0.38) | CYP19A1NQO2KDM4ELMNASOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143448-A1 | HYDROGENATION OF L-SORBOSE | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143448-A1 | HYDROGENATION OF L-SORBOSE | LDHA, ALPL, MPI | CYP19A1 3152/4885NQO2 1144/4885KDM4E 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.